Mahmoud Zureik discusses risk of bleeding in patients with non-valvular atrial fibrillation who switched and those who remained on a vitamin K antagonist.
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv